Login to Your Account

Keeping 'Options' Open

Isis, Biogen Ink Second Rare Disease Deal; Targeting DM1

By Jennifer Boggs
Managing Editor

Wednesday, August 8, 2012

Six months after signing an option agreement on a Phase I-stage antisense program in spinal muscular atrophy (SMA), Isis Pharmaceuticals Inc. and Biogen Idec Inc. agreed to a similarly structured deal for an earlier-stage rare disease program targeting myotonic dystrophy Type I (DM1), a muscular wasting disease also known as Steinert disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription